Envisagenics

Envisagenics is a biotechnology company focused on turning RNA insights into potential therapies. Its AI platform, SpliceCore®, supports the discovery and therapeutic targeting of RNA splicing, an area the company describes as an underused source of drug targets. By combining expertise in RNA biology with artificial intelligence, Envisagenics seeks to identify high-impact, novel targets that traditional discovery methods may miss. The company applies this approach to oncology and neurodegeneration, with the aim of advancing breakthrough treatments for patients.

Envisagenics presents its work as an integrated path from RNA-based discovery toward therapeutic impact. Its activities center on analyzing RNA splicing, identifying promising targets, and developing ways to address them therapeutically. The company emphasizes science-led research and a collaborative, patient-driven team committed to delivering life-changing treatments. Through its platform and research pipeline, Envisagenics works to translate advances in RNA biology into potential treatment opportunities. Its website also provides information about the company’s science, pipeline, careers, and news, reflecting its focus on research and progress toward patient-centered therapies.